Reductive heme-dependent activation of the N-oxide prodrug AQ4N by nitric oxide synthase

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 5118-5120

  Nishida, Clinton R ^a   Ortiz De Montellano, Paul R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; HEME; IRON; NITRIC OXIDE SYNTHASE; PRODRUG;

ARTICLE; ATOM; CONCENTRATION (PARAMETERS); TIME;

ANAEROBIOSIS; ANTHRAQUINONES; BINDING SITES; CYTOCHROME P-450 CYP3A; HEME; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PRODRUGS;

EID: 50249160554     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800496s     Document Type: Article

References (29)

1. (a) Brown, M. J. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med Today 2000, 6, 157-162.
2. (b) Lee, K.; Roth, R. A.; LaPres, J. J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther. 2007, 113, 229-246.
3. Brown, M. J. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999, 59, 5863-5870.
4. Tomasz, M. Mitomycin C: small, fast and deadly (but very selective). Chem. Biol. 1995, 2, 575-579.
5. Papadopoulou, M. V.; Bloomer, W. D. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin. Cancer Res. 2003, 9, 5714-5720.
6. Seow, H. A.; Penketh, P. G.; Shyam, K.; Rockwell, S.; Sartorelli, A. C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy-]carbonyl] hydrazine: an anticancer agent targeting hypoxic cells. Proc. Nat. Acad. Sci. U.S.A. 2005, 102, 9282-9287.
7. (a) Lalani, A. S.; Alters, S. E.; Wong, A.; Albertella, M. R.; Cleland, J. L.; Henner, W. D. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin. Cancer. Res. 2007, 13, 2216-2225.
8. (b) Patterson, L. H. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab. Rev. 2002, 34, 581-592.
9. (a) Walton, M. I.; Wolf, C. R.; Workman, P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol. 1992, 44, 251-259.
10. (b) Sartorelli, A. C.; Hodnick, W. F.; Belcourt, M. F.; Tomasz, M.; Haffty, B.; Fischer, J. J.; Rockwell, S. Mitomycin C: a prototype bioreductive agent. Oncol. Res. 1994, 6, 501-508.
11. (a) Garner, A. P.; Paine, M. J. I.; Rodríguez-Crespo, I.; Chinje, E. C.; Ortiz de Montellano, P. R.; Stratford, I. J.; Tew, D. G.; Wolf, C. R. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 1999, 59, 1929-1934.
12. (b) Jiang, H.-B.; Ichikawa, M.; Furukawa, A.; Tomita, S.; Ichikawa, Y. Reductive activation of mitomycin C by neuronal nitric oxide synthase. Biochem. Pharmacol. 2000, 60, 571-579.
13. (c) Kumagai, Y.; Nakajima, H.; Midorikawa, K.; Homma-Takeda, S.; Shimojo, N. Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: nitric oxide synthase as a quinone reductase. Chem. Res. Toxicol. 1998, 11, 608-613.
14. (d) Matsuda, H.; Kimura, S.; Iyanagi, T. One-electron reduction of quinones by the neuronal nitric-oxide synthase reductase domain. Biochim. Biophys. Acta 2000, 1459, 106-116.
15. (a) Atik, E.; Ergin, M.; Erdogan, S.; Tuncer, I. Inducible nitric oxide synthase and apoptosis in human B cell lymphomas. Mol. Cell. Biochem. 2006, 290, 205-209.
16. (b) Förstermann, U.; Gorksy, L. D.; Pollock, J. S.; Ishii, K.; Schmidt, H. H.; Heller, M.; Murad, F. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin. Mol. Pharmacol. 1990, 38, 7-13.
17. (c) Jenkins, D. C.; Charles, I. G.; Baylis, S. A.; Lelchuk, R.; Radomski, M. W.; Moncada, S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br. J. Cancer 1994, 70, 847-849.
18. 2+/calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180. Biochem. J. 1993, 289, 357-361.
19. (e) Cobbs, C. S.; Brenman, J. E.; Aldape, K. D.; Bredt, D. S.; Israel, M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995, 55, 727-730.
20. (f) Ambs, S.; Merriam, W. G.; Bennett, W. P.; Felley-Bosco, E.; Ogunfusika, M. O.; Oser, S. M.; Klein, S.; Shields, P. G.; Billiar, T. R.; Harris, C. C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58, 334-341.
21. (g) Thomsen, L. L.; Sargent, J. M.; Williamson, C. J. H.; Elgie, A. W. Nitric oxide synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem. Pharmacol. 1998, 56, 1365-1370.
22. (a) Patterson, L. H.; Craven, M. R.; Fisher, G. R.; Teesdale-Spittle, P. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol. Res. 1994, 6, 533-538.
23. (b) Smith, P. J.; Blunt, J. N.; Desnoyers, R.; Giles, Y.; Patterson, L. H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N- oxides. Cancer Chemother. Pharmacol. 1997, 39, 455-461.
24. (a) Raleigh, S. M.; Wanogho, E.; Burke, M. D.; McKeown, S. R.; Patterson, L. H. Involvement of human hepatic cytochrome P450(CYP's) in the reductive metabolism of AQ4N, a novel anthraquinone based antineoplastic prodrug. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 763-767.
25. (b) Yakkundi, A.; McErlane, V.; Murray, M.; McCarthy, H. O.; Ward, C.; Hughes, C. M.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R.; Robson, T. Tumour selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 2006, 13, 598-605.
26. Patterson, L. H.; McKeown, S. R.; Robson, T.; Gallagher, R.; Raleigh, S. M.; Orr, S. Anti-tumour pro-drug development using cytochrome P450 mediated activation. Anti-Cancer Drug Des. 1999, 14, 473-486.
27. 13b
28. (b) Gevantman, L. H. Solubility of Selected Gases in Water. In CRC Handbook of Chemistry and Physics, 88th ed.; Lide D. R., Ed.; CRC Press: Boca Raton, FL, 2007; Chapter 8, pp 80-83.
29. Stuehr, D. J.; Cho, H. J.; Kwon, N. S.; Weise, M. F.; Nathan, C. F. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7773-7777.